Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current perspectives on statins.

D J Maron1, S Fazio, M F Linton

  • 1Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University, School of Medicine, Nashville, TN 37232-6300 , USA. david.maron@mcmail.vanderbilt.edu

Circulation
|January 19, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Observation of Charmonium Sequential Suppression in Heavy-Ion Collisions at the Relativistic Heavy Ion Collider.

Physical review letters·2026
Same author

Energy Independence of the Collins Asymmetry in p^{↑}p Collisions.

Physical review letters·2026
Same author

Tirbanibulin 1% real-world use in 679 actinic keratoses patients during warm season (SUMM-AK study).

Journal of the European Academy of Dermatology and Venereology : JEADV·2025
Same author

Precision Measurement of Net-Proton-Number Fluctuations in Au+Au Collisions at RHIC.

Physical review letters·2025
Same author

Measurement of Two-Point Energy Correlators within Jets in p+p Collisions at sqrt[s]=200  GeV.

Physical review letters·2025
Same author

Onset of Constituent Quark Number Scaling in Heavy-Ion Collisions at RHIC.

Physical review letters·2025
Same journal

Eugene Braunwald, MD, 1929-2026.

Circulation·2026
Same journal

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

Circulation·2026
Same journal

Advancing Quality in the Evaluation, Surveillance, and Management of Aortic Stenosis: A Report From the AHA Target: AS Registry.

Circulation·2026
Same journal

Heart Failure Occurring in the Perinatal Period: A Scientific Statement From the American Heart Association.

Circulation·2026
Same journal

Correction to: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Circulation·2026
Same journal

Correction to: The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis.

Circulation·2026
See all related articles

Statins effectively lower LDL cholesterol and triglycerides, reducing major coronary events by about 30%. These widely used drugs are well-tolerated and may offer benefits beyond lipid reduction.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Statins (HMG-CoA reductase inhibitors) are primary treatments for hypercholesterolemia.
  • They effectively lower low-density lipoprotein (LDL) and triglyceride levels.

Purpose of the Study:

  • To review the efficacy and safety of statins.
  • To explore the mechanisms behind statin-mediated cardiovascular benefits.

Main Methods:

  • Analysis of clinical trial data in diverse patient populations.
  • Review of proposed pharmacological and non-pharmacological mechanisms of action.

Main Results:

  • Statins consistently reduce the relative risk of major coronary events by approximately 30%.
  • Greater absolute benefits are observed in patients with higher baseline cardiovascular risk.

Related Experiment Videos

  • Statins are generally well-tolerated with an excellent safety profile.

    • Conclusions:

    • Statins are highly effective in managing hypercholesterolemia and reducing cardiovascular events.
    • Mechanisms beyond LDL lowering, including anti-inflammatory and plaque-stabilizing effects, contribute significantly to their benefits.
    • Statins may evolve into broader antiatherogenic agents.